Nothing Special   »   [go: up one dir, main page]

SI3185867T1 - Postopek kristalizacije aripiprazolnih derivatov v formulacijah s podaljšanim sproščanjem za zdravljenje shizofrenije - Google Patents

Postopek kristalizacije aripiprazolnih derivatov v formulacijah s podaljšanim sproščanjem za zdravljenje shizofrenije

Info

Publication number
SI3185867T1
SI3185867T1 SI201531576T SI201531576T SI3185867T1 SI 3185867 T1 SI3185867 T1 SI 3185867T1 SI 201531576 T SI201531576 T SI 201531576T SI 201531576 T SI201531576 T SI 201531576T SI 3185867 T1 SI3185867 T1 SI 3185867T1
Authority
SI
Slovenia
Prior art keywords
schizophrenia
treatment
extended release
release formulations
crystallization process
Prior art date
Application number
SI201531576T
Other languages
English (en)
Inventor
Wilfredo Morales Jr.
Tarek A. Zeidan
Renato A. Chiarella
Steven G. Wright
Jason M. Perry
Original Assignee
Alkermes Pharma Ireland Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alkermes Pharma Ireland Limited filed Critical Alkermes Pharma Ireland Limited
Publication of SI3185867T1 publication Critical patent/SI3185867T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
SI201531576T 2014-08-25 2015-08-24 Postopek kristalizacije aripiprazolnih derivatov v formulacijah s podaljšanim sproščanjem za zdravljenje shizofrenije SI3185867T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462041341P 2014-08-25 2014-08-25
EP15836431.5A EP3185867B1 (en) 2014-08-25 2015-08-24 Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia
PCT/US2015/046525 WO2016032950A1 (en) 2014-08-25 2015-08-24 Crystallization process of aripiprazole derivatives in extended release formulations for treatment of schizophrenia

Publications (1)

Publication Number Publication Date
SI3185867T1 true SI3185867T1 (sl) 2021-08-31

Family

ID=55347322

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531576T SI3185867T1 (sl) 2014-08-25 2015-08-24 Postopek kristalizacije aripiprazolnih derivatov v formulacijah s podaljšanim sproščanjem za zdravljenje shizofrenije

Country Status (19)

Country Link
US (5) US10064859B2 (sl)
EP (2) EP3185867B1 (sl)
JP (2) JP6591546B2 (sl)
CN (2) CN107106556B (sl)
AU (2) AU2015306910B2 (sl)
CA (1) CA2959329C (sl)
CY (1) CY1124058T1 (sl)
DK (1) DK3185867T3 (sl)
ES (1) ES2862098T3 (sl)
HR (1) HRP20210551T1 (sl)
HU (1) HUE054641T2 (sl)
IL (1) IL250661B (sl)
LT (1) LT3185867T (sl)
MA (2) MA40480B1 (sl)
PL (1) PL3185867T3 (sl)
PT (1) PT3185867T (sl)
RS (1) RS61709B1 (sl)
SI (1) SI3185867T1 (sl)
WO (1) WO2016032950A1 (sl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10016415B2 (en) 2014-08-18 2018-07-10 Alkermes Pharma Ireland Limited Aripiprazole prodrug compositions
PT3185867T (pt) * 2014-08-25 2021-04-12 Alkermes Pharma Ireland Ltd Processo de cristalização de derivados de aripiprazol em formulações de libertação prolongada para tratamento de esquizofrenia
WO2016181406A1 (en) * 2015-05-08 2016-11-17 Davuluri Ramamohan Rao Improved process for the preparation of aripiprazole with reduced particle size
WO2018104953A1 (en) * 2016-12-07 2018-06-14 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 7-{4-[4-(2,3-dichlorophenyl)-piperazin-1-yl]butoxy}-2oxo-3,4-dihydro-2h-quinolin-1-yl)methyl dodecanoate
JP7246364B2 (ja) 2017-07-28 2023-03-27 インテルキム、ソシエダッド アノニマ アリピプラゾールラウロキシルの調製方法
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
CA3092335A1 (en) 2018-03-05 2019-09-12 Alkermes Pharma Ireland Limited Aripiprazole dosing strategy
CN113105389B (zh) * 2021-04-16 2022-04-08 江苏海洋大学 一种阿立哌唑药物共晶及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
AR033485A1 (es) * 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
US20050032811A1 (en) 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
TWI371274B (en) * 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
PL1675573T4 (pl) * 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
US9248048B2 (en) * 2007-08-03 2016-02-02 Neodyne Biosciences, Inc. Wound or skin treatment devices and methods
JP5825786B2 (ja) 2007-12-19 2015-12-02 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ 長時間作用型注入可能パリペリドンエステルに関連する投薬計画
US20110003823A1 (en) 2008-08-01 2011-01-06 Alpha Synergy Development, Inc. Compositions and methods for treatment of diseases and conditions associated with vasodilation and/or vascular leakage
FI2445502T4 (fi) * 2009-06-25 2023-01-13 Heterosyklisiä yhdisteitä neurologisten ja psykologisten häiriöiden hoitamiseksi
WO2012077134A1 (en) * 2010-12-07 2012-06-14 Ind-Swift Laboratories Limted Process for preparing aripiprazole polymorphs
RS55434B1 (sr) * 2011-03-18 2017-04-28 Alkermes Pharma Ireland Ltd Injektabilne farmaceutske kompozicije koje sadrže antipsihotik koji je nerastvorljiv u vodi, sorbitan laurat i polisorbat 20
JP6471089B2 (ja) * 2012-03-19 2019-02-13 アルカームス ファーマ アイルランド リミテッド 脂肪酸エステルを含む医薬組成物
ES2792149T3 (es) * 2012-09-19 2020-11-10 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas que tienen estabilidad de almacenamiento mejorada
PT3185867T (pt) * 2014-08-25 2021-04-12 Alkermes Pharma Ireland Ltd Processo de cristalização de derivados de aripiprazol em formulações de libertação prolongada para tratamento de esquizofrenia

Also Published As

Publication number Publication date
ES2862098T3 (es) 2021-10-07
US10478434B2 (en) 2019-11-19
CA2959329A1 (en) 2016-03-03
HRP20210551T1 (hr) 2021-08-20
IL250661A0 (en) 2017-04-30
JP2019210296A (ja) 2019-12-12
CN107106556A (zh) 2017-08-29
IL250661B (en) 2020-04-30
US20190015408A1 (en) 2019-01-17
CN111454207A (zh) 2020-07-28
US10064859B2 (en) 2018-09-04
CA2959329C (en) 2023-06-27
NZ729479A (en) 2021-03-26
PL3185867T3 (pl) 2021-11-22
US20160051546A1 (en) 2016-02-25
CN111454207B (zh) 2024-10-18
AU2015306910A1 (en) 2017-03-16
US20210205302A1 (en) 2021-07-08
JP2017526747A (ja) 2017-09-14
PT3185867T (pt) 2021-04-12
LT3185867T (lt) 2021-06-10
AU2020264303B2 (en) 2022-10-13
MA55917A (fr) 2022-03-16
EP3185867A1 (en) 2017-07-05
US20240245676A1 (en) 2024-07-25
CY1124058T1 (el) 2022-05-27
US10973816B2 (en) 2021-04-13
WO2016032950A1 (en) 2016-03-03
JP6591546B2 (ja) 2019-10-16
EP3865476A1 (en) 2021-08-18
HUE054641T2 (hu) 2021-09-28
US11883394B2 (en) 2024-01-30
AU2020264303A1 (en) 2020-11-26
CN107106556B (zh) 2020-06-05
US20200108063A1 (en) 2020-04-09
RS61709B1 (sr) 2021-05-31
MA40480B1 (fr) 2021-08-31
EP3185867A4 (en) 2018-01-24
EP3865476B1 (en) 2024-08-14
DK3185867T3 (da) 2021-03-15
AU2015306910A8 (en) 2020-11-19
AU2015306910B2 (en) 2020-11-19
EP3185867B1 (en) 2021-01-13

Similar Documents

Publication Publication Date Title
IL250661B (en) Crystallization process of antecedents of aripiprazole in sustained-release formulations for the treatment of schizophrenia
HK1225968A1 (zh) 用於治療hbv感染的組合療法
RS63231B1 (sr) Primena derivata hinolina u lečenju upalnih bolesti
IL249502B (en) New therapeutic uses of benzylideneguanidine derivatives for the treatment of diseases caused by structurally abnormal proteins
HK1258994A1 (zh) 用於疾病治療的方法
SI3097085T1 (sl) Derivati benzoksazinona za zdravljenje kožnih bolezni
HK1232220A1 (zh) 用於治療心血管疾病的 -苄基異喹啉衍生物
PT3142641T (pt) Formulações para o tratamento de hipertiroidismo
IL248568A0 (en) A process for the preparation of dihydroisoxazole derivatives
HK1248551A1 (zh) 用於治療精神分裂症的伊潘立酮
PL3223799T3 (pl) Sposób otrzymywania kompozycji składnik farmaceutyczny-polimer
EP3100734A4 (en) Use of camptothecin derivative in preparing pharmaceutical used for treating multiple myeloma
HK1232209A1 (zh) 製備 -乙酰氧基丙酸及其衍生物的方法
HUP1400545A2 (hu) Eljárás benzazepin származékok elõállítására
HUP1400518A2 (hu) Eljárás tofacitinib elõállítására
PL3331517T3 (pl) Zastosowanie hydroksymocznika w celu zapobiegania brakowi perfuzji w siatkówce
GB201418268D0 (en) Composition & methods of treatment
GB201418272D0 (en) Composition & methods of treatment